Metabolic biomarkers for memory loss
The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
1. A method of treating memory impairment in a subject, the method comprising
a) analyzing at least one plasma sample from the subject in a fasting state to determine the concentrations of each component of a set of metabolites, wherein the components comprise C3, phosphocholine (PC) aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, C12:1, C16:2, C10:1, asparagine (Asn) and asymmetric dimethylarginine (ADMA), and
b) administering a treatment for memory impairment to the subject when:
(i) the concentrations of the components C3, PC aa C32:0, PC aa C40:5, C5-OH (C3-DC-M), PC ae C34:0, C18:1-OH, PC aa C34:4, PC aa C38:4, C5, PC aa C38:3, lysoPC a C18:0, C10:2, Asn, and ADMA in the subject's set of metabolites are lower as compared to their concentrations in a set of metabolites from subjects determined to define normal concentrations, and
(ii) the concentrations of the components C12:1, C16:2, and C10:1 in the subject's set of metabolites are higher as compared to their concentrations in the set of metabolites from subjects determined to define normal concentrations.
2. The method of claim 1 , wherein the normal concentrations comprise concentrations of each component of the subject's set of metabolites prior to the onset of memory impairment.
3. The method of claim 1 , wherein the normal concentrations comprise concentrations of each component from a population of individuals that do not display memory impairment.
4. The method of claim 1 , wherein the concentrations of the set of metabolites from the subject are measured using mass spectroscopy.
5. The method of claim 1 , further comprising monitoring effectiveness of the treatment for memory impairment.